OCUL Ocular Therapeutix

Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)--

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at three upcoming investor conferences:

  • 2017 BIO CEO & Investor Conference

    Monday, February 13, 2017 at 8:30 a.m. Eastern Time

    The Waldorf Astoria New York, New York, NY
  • 2017 RBC Capital Markets Global Healthcare Conference

    Thursday, February 23, 2017 at 9:00 a.m. Eastern Time

    The New York Palace Hotel, New York, NY
  • 37th Annual Cowen and Company Healthcare Conference

    Monday, March 6, 2017 at 2:40 p.m. Eastern Time

    The Boston Marriott Copley Place, Boston, MA

Live audio webcasts of the presentations can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix has resubmitted a new drug application (NDA) for post-surgical pain for its lead product candidate, DEXTENZA, which has completed Phase 3 clinical development for post-surgical ocular inflammation and pain. Subject to the approval of the NDA for post-surgical ocular pain, Ocular Therapeutix intends to submit a supplemental NDA for DEXTENZA to broaden its label to include an indication for post-surgical inflammation. DEXTENZA is also in Phase 3 clinical development for allergic conjunctivitis. OTX-TP is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

EN
09/02/2017

Underlying

OCULOcular Therapeutix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocular Therapeutix

 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Participate in September Investor and Scientifi...

Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences BEDFORD, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September 2025. Upcoming Investor Conferences Morgan Stanley 23rd Annual Global Healthcare Conference:Fireside Chat Date/Time: Monday, September 8, 2025Fireside Chat Time: 2:35 – 3:10 PM ETPresenter: Pravin U. Dugel, MD, Executi...

15h / 18m 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Asse...

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR Ocular plans to outline clinical trial design, timing, and development strategy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) at its Investor Day on September 30, 2025 BEDFORD, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced it has received written agreement regarding a registrati...

August 12, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and ...

Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study for both SOL trials Ocular to host Investor Day on Tuesday, September 30, 2025, in New York City Raised gross proceeds of approximately $97 million in June 2025 through existing ATM facility Cash balance o...

August 5, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on...

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025 BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, August 5, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2025. Conference Call and Webcast Information: Date: Tuesday, August 5, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1-877...

July 29, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025. 8th Annual OIS Retina Innovation Summit (OIS Retina 2025): Long Beach, CA Company Presentation: Ocular Therapeutix Session: Spotlight on Drug DeliverySession Date/Time: Tuesday, July 29, 2025, 11:00 AM – 12:35 PM PTPresenter: Sanjay Nayak, MBBS, Ph...

July 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch